Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Cipro
gptkb:drug |
| gptkbp:activities |
inhibits vitamin K epoxide reductase
|
| gptkbp:approves |
gptkb:1954
gptkb:FDA |
| gptkbp:brand |
gptkb:Coumadin
gptkb:Jantoven |
| gptkbp:contraindication |
pregnancy
severe liver disease active bleeding |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
gptkb:tablet
injection 2-10 mg daily |
| gptkbp:education |
report any unusual bleeding
avoid foods high in vitamin K inform healthcare providers about use monitor INR regularly |
| https://www.w3.org/2000/01/rdf-schema#label |
warfarin
|
| gptkbp:ingredients |
C19 H16 O4
|
| gptkbp:interacts_with |
antibiotics
antifungals NSAI Ds certain herbal supplements |
| gptkbp:is_atype_of |
B01 A A03
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_monitored_by |
INR (International Normalized Ratio)
|
| gptkbp:is_used_for |
preventing blood clots
treating deep vein thrombosis treating pulmonary embolism preventing stroke in patients with atrial fibrillation |
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver oral administration anticoagulant effect delayed onset of action |
| gptkbp:related_to |
gptkb:hospital
gptkb:deep_vein_thrombosis gptkb:atrial_fibrillation anticoagulation therapy thrombosis vitamin K pulmonary embolism stroke prevention embolism blood thinner |
| gptkbp:side_effect |
nausea
bruising bleeding hair loss skin necrosis |
| gptkbp:type_of |
81-81-2
|